Tue, December 13, 2022

Vikram Purohit Maintained (ARQT) at Buy with Increased Target to $51 on, Dec 13th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-51-on-dec-13th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Vikram Purohit of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Increased Target from $49 to $51 on, Dec 13th, 2022.

Vikram has made no other calls on ARQT in the last 4 months.



There are 2 other peers that have a rating on ARQT. Out of the 2 peers that are also analyzing ARQT, 0 agree with Vikram's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Vikram


  • Sean Kim of "JonesTrading" Initiated at Strong Buy and Held Target at $54 on, Thursday, September 22nd, 2022
  • Serge Belanger of "Needham" Initiated at Strong Buy and Held Target at $46 on, Wednesday, September 7th, 2022